Clinical trial
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney…
NCT00183248 · University of Miami, Other · Completed
Key facts
| NCT number | NCT00183248 |
|---|---|
| Title | Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients |
| Official title | Pilot Study Using Donor Stem Cells and Campath-1H to Induce Renal Transplant Tolerance (ITN022ST) |
| Lead sponsor | University of Miami, Other |
| Collaborators | Immune Tolerance Network (ITN) |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Transplantation, Kidney Disease, Kidney Failure |
| Intervention type | Drug, Procedure |
| Interventions | Alemtuzumab, Mycophenolate mofetil, Sirolimus, Tacrolimus, Donor bone marrow stem cell infusion, Kidney transplant |
| Enrollment | 9 |
| Start date | Sep 1, 2004 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Sep 16, 2005 |
| Last update posted | Oct 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: